Ignite Creation Date:
2025-12-24 @ 2:23 PM
Ignite Modification Date:
2026-02-02 @ 6:35 PM
Study NCT ID:
NCT04044859
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-03-13
First Post:
2019-07-03
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
Sponsor:
Adaptimmune
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Endometrial Cancer | View |
| None | Esophageal Cancer | View |
| None | Esophagogastric Junction (EGJ) | View |
| None | Gastric (Stomach) Cancer | View |
| None | Head and Neck Cancer | View |
| None | Melanoma | View |
| None | Ovarian Cancer | View |
| None | Non-small Cell Lung (NSCLC) | View |
| None | Urothelial Cancer | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Cell Therapy | View |
| None | T Cell Therapy | View |
| None | SPEAR T Cell | View |
| None | MAGE-A4 | View |
| None | Immuno-oncology | View |
| None | Metastatic | View |
| None | Urothelial | View |
| None | Head and Neck | View |
| None | Gastric (stomach) | View |
| None | Esophagogastric Junction (EGJ) | View |
| None | Non-small Cell Lung (NSCLC) | View |
| None | Esophageal Cancer | View |
| None | Ovarian Cancer | View |
| None | Endometrial Cancer | View |
| None | Melanoma | View |